USP7 and prostate cancer: The hormone-sensitive LNCaP prostate cancer cell lines, that show appreciable levels of USP7 (Figure 1A), were treated with various concentrations of the USP7 inhibitor P5091 or vehicle, with or without DHT stimulation.